Innovation in anti Human Immunodeficiency Virus
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "HIV Vaccines".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2273
Special Issue Editor
Interests: HIV-1; HIV-1 associated neurocognitive disorders; neurovirology; Alzheimer disease; endolysosomes and autophagy; innate immunity; coronaviruses
Special Issue Information
Dear Colleagues,
Human immunodeficiency virus is a virus that causes a deficiency of the human immune system. HIV destroys the body's T lymphocytes, thus blocking cellular and humoral immunity processes, resulting in immune system paralysis, which leads to the spread of various diseases in the body, and eventually AIDS. Due to the extremely rapid mutation of HIV, it is difficult to produce a specific vaccine, so far there is no effective treatment, posing a great threat to human health.
There is therefore an urgent need for further research into HIV's function to help researchers develop new treatments that can effectively fight the disease. In this regard, we have launched this Vaccine Special Issue (MDPI), and we welcome your valuable contributions in the form of an influential article focusing on the theme "Innovation in anti Human Immunodeficiency Virus".
We encourage and welcome submissions of manuscripts regarding the following topics:
- Perspectives and reviews regarding the human immunodeficiency virus;
- Original or review articles regarding human immunodeficiency virus: analysis and detection;
- Case reports or case series of AIDS with typical or atypical presentation;
- Developing and improving new technologies or vaccines for use against immunodeficiency-based viruses.
Dr. Khan Nabab
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune
- HIV
- diseases
- vaccine
- virus
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
